GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.
Prospective Study of Single Subject Cortical Thickness as an Early Diagnostic Biomarker of Frontotemporal Dementia
Étude clinique de phase 2 sur l’ocytocine intranasale pour la démence fronto-temporale
Étude randomisée, en double aveugle, contre placebo, visant à évaluer l’innocuité, la tolérabilité, la pharmacocinétique et la pharmacodynamique de multiples administrations de bolus d’ISIS 814907 à doses croissantes par voie intrathécale (IT) à des patients atteints d’une forme légère de la maladie d’Alzheimer
Quantitative Magnetic Resonance Imaging of oxygen transport: a new window on mitochondrial dysfunction in Alzheimer’s disease, Phase 3: data acquisition in individuals affected by Alzheimer’s disease and demographically-matched control participants.